» Articles » PMID: 36153522

Application of MOF-based Nanotherapeutics in Light-mediated Cancer Diagnosis and Therapy

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2022 Sep 24
PMID 36153522
Authors
Affiliations
Soon will be listed here.
Abstract

Light-mediated nanotherapeutics have recently emerged as promising strategies to precisely control the activation of therapeutic reagents and imaging probe both in vitro and in vivo, largely ascribed to their unique properties, including minimally invasive capabilities and high spatiotemporal resolution. Nanoscale metal-organic frameworks (NMOFs), a new family of hybrid materials consisting of metal attachment sites and bridging ligands, have been explored as a new platform for enhanced cancer diagnosis and therapy due to their tunable size, modifiable surface, good biocompatibility, high agent loading and, most significantly, their ability to be preferentially deposited in tumors through enhanced permeability and retention (EPR). Especially the light-driven NMOF-based therapeutic platform, which not only allow for increased laser penetration depth and enhanced targeting, but also enable imaging-guided or combined treatments. This review provides up-to-date developments of NMOF-based therapeutic platforms for cancer treatment with emphasis on light-triggered therapeutic strategies and introduces their advances in cancer diagnosis and therapy in recent years.

Citing Articles

Cascade-catalysed nanocarrier degradation for regulating metabolism homeostasis and enhancing drug penetration on breast cancer.

Zhang F, Cheng K, Zhang X, Zhou S, Zou J, Tian M J Nanobiotechnology. 2024; 22(1):680.

PMID: 39506777 PMC: 11542379. DOI: 10.1186/s12951-024-02948-w.


Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.

Li J, Luo P, Liu S, Fu M, Lin A, Liu Y Mater Today Bio. 2024; 27:101149.

PMID: 39100279 PMC: 11296058. DOI: 10.1016/j.mtbio.2024.101149.


MOFs for next-generation cancer therapeutics through a biophysical approach-a review.

Shano L, Karthikeyan S, Kennedy L, Chinnathambi S, Pandian G Front Bioeng Biotechnol. 2024; 12:1397804.

PMID: 38938982 PMC: 11208718. DOI: 10.3389/fbioe.2024.1397804.


Advancements and Challenges in the Application of Metal-Organic Framework (MOF) Nanocomposites for Tumor Diagnosis and Treatment.

Hou Y, Zhu C, Ban G, Shen Z, Liang Y, Chen K Int J Nanomedicine. 2024; 19:6295-6317.

PMID: 38919774 PMC: 11198007. DOI: 10.2147/IJN.S463144.


Nanocomposites Based on Magnetic Nanoparticles and Metal-Organic Frameworks for Therapy, Diagnosis, and Theragnostics.

Picchi D, Biglione C, Horcajada P ACS Nanosci Au. 2024; 4(2):85-114.

PMID: 38644966 PMC: 11027209. DOI: 10.1021/acsnanoscienceau.3c00041.


References
1.
Dekrafft K, Boyle W, Burk L, Zhou O, Lin W . Zr- and Hf-based nanoscale metal-organic frameworks as contrast agents for computed tomography. J Mater Chem. 2012; 22(35):18139-18144. PMC: 3462458. DOI: 10.1039/C2JM32299D. View

2.
Chowdhuri A, Bhattacharya D, Sahu S . Magnetic nanoscale metal organic frameworks for potential targeted anticancer drug delivery, imaging and as an MRI contrast agent. Dalton Trans. 2016; 45(7):2963-73. DOI: 10.1039/c5dt03736k. View

3.
Deng X, Liang S, Cai X, Huang S, Cheng Z, Shi Y . Yolk-Shell Structured Au Nanostar@Metal-Organic Framework for Synergistic Chemo-photothermal Therapy in the Second Near-Infrared Window. Nano Lett. 2019; 19(10):6772-6780. DOI: 10.1021/acs.nanolett.9b01716. View

4.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

5.
Lu K, He C, Lin W . A Chlorin-Based Nanoscale Metal-Organic Framework for Photodynamic Therapy of Colon Cancers. J Am Chem Soc. 2015; 137(24):7600-3. PMC: 4691355. DOI: 10.1021/jacs.5b04069. View